About 100 reports

  • Target
  • Official Title

HEART TRANSPLANT REJECTION THERAPEUTICS CLINICAL TRIALS, GLOBAL, BY END POINT STATUS, 2020* CLINICAL TRIALS BY END POINT STATUS HEART TRANSPLANT REJECTION THERAPEUTICS CLINICAL TRIALS, GLOBAL, BY END POINT STATUS, 2020* HEART TRANSPLANT REJECTION

  • Clinical Trial
  • Heart Transplant
  • Targeted Therapy
  • Transplantation
  • Vaccine
  • HEART TRANSPLANT REJECTION - PIPELINE BY HEAT BIOLOGICS INC, H1 2018
  • HEART TRANSPLANT REJECTION - PIPELINE BY NOXXON PHARMA AG, H1 2018

Heart transplant replaces an injured or diseased heart with a healthy one.

  • Heart Transplant
  • Medical Biotechnology
  • Targeted Therapy
  • World
  • Product Initiative
  • Target
  • Target

HEART TRANSPLANT REJECTION THERAPEUTICS CLINICAL TRIALS, GLOBAL, BY END POINT STATUS, 2017* CLINICAL TRIALS BY END POINT STATUS HEART TRANSPLANT REJECTION THERAPEUTICS CLINICAL TRIALS, GLOBAL, BY END POINT STATUS, 2017* HEART TRANSPLANT REJECTION

  • Clinical Trial
  • Heart Transplant
  • Targeted Therapy
  • Transplantation
  • Vaccine

WE ARE FULFILLING OUR PROMISE TO MAKE SEQUENCING BASED INFORMATION AVAILABLE TO THE TRANSPLANT CLINIC, NOW ALSO FOR HEART TRANSPLANT PATIENTS. "

  • Orthopedics
  • Vaccine
  • Canada
  • North America
  • Market Size

Liver transplant replaces an injured or diseased liver with a healthy one.

  • General Medicine And Specialty Medicine
  • Liver Transplant
  • Targeted Therapy
  • Transplantation
  • Vaccine

The prominent features of this report are - ##.

  • Medical Biotechnology
  • Pharmaceutical
  • Targeted Therapy
  • Vaccine
  • World

Food and Drug Administration (FDA), World Health Organization (WHO), GLOBOCAN, and various organ transplant registries.

  • Medical Device
  • Orthopedics
  • North America
  • United States
  • Zimmer Biomet Holdings, Inc.

The prominent features of this report are - ##.

  • Medical Biotechnology
  • Pharmaceutical
  • Targeted Therapy
  • Vaccine
  • World

Significant survival advantages for the abatacept group were demonstrated at one-year post-transplant.

  • Immunotherapy
  • Targeted Therapy
  • Therapy
  • Vaccine
  • Bristol-Myers Squibb Company
  • DORMANT PRODUCTS, H2 2018 (CONTD..1), H2 2018

## ## ## Universities/ Institutes ## ## ## ## ## ## PRODUCTS UNDER DEVELOPMENT BY INDICATION NUMBER OF PRODUCTS UNDER DEVELOPMENT BY TOP ## INDICATIONS, H## 2018 NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H## 2018 Indication Source: Global Markets Dire

  • Immunotherapy
  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy
  • Vaccine

Hoffmann-La Roche Ltd Cytokinetics Inc ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## UCB SA Roivant Sciences Ltd Argenx SE ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Amarin Corp Plc ## ## ## ##

  • Clinical Trial
  • Neurological Disorder
  • Pharmaceutical
  • Targeted Therapy
  • Vaccine
  • 5. All the trials included are unique trials.

P. A. ", Italy) GDCT## GDC##, MFM## Immunology Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Lupus Nephritis, Transplant Rejection Completed Phase I Interventional

  • Clinical Trial
  • Genitourinary System Disease
  • Musculoskeletal Disorder
  • Targeted Therapy
  • Vaccine

Patients will be randomized in a ##:##:## fashion to placebo or one of two different doses of AG## on a background of stable heart failure therapy.

  • Endocrine Disease
  • Targeted Therapy
  • Therapy
  • Vaccine
  • Alnylam Pharmaceuticals, Inc.

Three (##. ##%) additional patients enrolled in the study had discontinued treatment, including one participant who underwent cardiac transplantation for their disease.

  • Targeted Therapy
  • Therapy
  • Vaccine
  • World
  • Product Initiative
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Blood Disease
  • Drug Development
  • Targeted Therapy
  • Vaccine
  • Novartis AG

The prominent features of this report are - ##.

  • Pharmaceutical
  • Targeted Therapy
  • Vaccine
  • World
  • Conatus Pharmaceuticals Inc.
  • DORMANT PRODUCTS, H2 2019 (CONTD..1), H2 2019

## Total ## Products in Phase II/ III and I/ II are reflected under Phase III and Phase II, respectively Source: Global Markets Direct NUMBER OF PRODUCTS UNDER DEVELOPMENT BY STAGE OF DEVELOPMENT, H## 2019 Stage of Development Number of Products Under Development PRODUCTS UNDER DEVELO

  • Immunotherapy
  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy
  • Vaccine
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Musculoskeletal Disorder
  • Neurological Disorder
  • Targeted Therapy
  • Therapy
  • Vaccine

The prominent features of this report are - ##.

  • Cardiovascular Disease
  • Clinical Trial
  • Targeted Therapy
  • Therapy
  • Vaccine
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2019 (CONTD..4), H1 2019
  • DORMANT PRODUCTS, H1 2019 (CONTD..1), H1 2019

MP## is currently in phase ##.

  • Immunotherapy
  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy
  • Vaccine
  • CLINICAL TRIAL PROFILE SNAPSHOTS
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

None of these QT abnormalities resulted in adverse cardiac events.

  • Digestive System Disorder
  • Pharmaceutical
  • Targeted Therapy
  • Vaccine
  • World
  • CLINICAL TRIAL PROFILE SNAPSHOTS

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • Medical Biotechnology
  • Monoclonal Antibody
  • Targeted Therapy
  • Vaccine
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

Hoffmann-La Roche Ltd Shionogi & Co Ltd Jiangsu Hengrui Medicine Co Ltd ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## CSL Ltd ## ## ## ## ## ## ## ## ##SBio Inc Source: GlobalData' s Pharma Intelligence Center

  • Blood Disease
  • Targeted Therapy
  • Therapy
  • Vaccine
  • GlaxoSmithKline plc

CLINICAL TRIALS BY PHASE IN G## COUNTRIES LUNG TRANSPLANT REJECTION THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2017* LUNG TRANSPLANT REJECTION THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2017* LUNG TRANSPLANT REJECTION THERAPEUTICS, G## COUNTRIES, CLINIC

  • Clinical Trial
  • Drug Development
  • Targeted Therapy
  • Vaccine
  • Novartis AG
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Clinical Trial
  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy
  • Vaccine

The prominent features of this report are - ##.

  • Medical Biotechnology
  • Targeted Therapy
  • Vaccine
  • World
  • Product Initiative

GDCT ID is the unique ID of GlobalData' s Pharma Intelligence Center clinical trial database Clinical Trial profile. ## Trial Title Official Title Trial Identifier Secondary ID(s) Therapy Area Indication(s) Biomarker(s) Trial Status Trial Phase Study Type Drug(s)/ Molecule(s) Sponsor

  • Monoclonal Antibody
  • Orthopedics
  • Targeted Therapy
  • Vaccine
  • World

Reddy' s Under Fasting Conditions GDCT## NCT##, BA## Immunology Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection Completed Phase I Interventional tacrolimus Dr.

  • Clinical Trial
  • Monoclonal Antibody
  • Targeted Therapy
  • Transplantation
  • Vaccine
  • AS-2553627 - DRUG PROFILE

TRANSPLANT REJECTION IS ONE OF THE KEY CHALLENGES OF ORGAN TRANSPLANTATION.

  • Health Services
  • Targeted Therapy
  • Therapy
  • Vaccine
  • United States

Hoffmann-La Roche Ltd ## ## ## ## ## ## Clinical Research and Biosciences India Private Limited (Inactive) ## ## ## ## ## ## ClinAssess GmbH ## ## ## ## ## ## Bavarian Nordic A/ S ## ## ## ## ## ## AstraZeneca Plc ## ## ## ## ## ## APT

  • Medical Biotechnology
  • Pharmaceutical
  • Targeted Therapy
  • World
  • Product Initiative